What's the Outlook for Arbutus Biopharma?

Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock.

Continue reading

Source Fool.com